Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2024-03-15
Disclosure Type: Results of Annual General Shareholders Meeting
💡 3-Second Summary
Samsung Biologics held its 13th Annual General Meeting of Shareholders, officially approving the financial statements for fiscal year 2023, which recorded consolidated revenue of KRW 3.69 trillion and operating profit of KRW 1.11 trillion. Additionally, Suh Seoung-hwan, a former Minister of Land, Infrastructure and Transport, was newly appointed as an outside director and audit committee member.
📊 1. [Summary of Core Disclosure Content and Major Figures]
- Date of Shareholders Meeting: March 15, 2024
- Approved FY2023 Financial Statements (Consolidated):
- Revenue: KRW 3,694,589M (Approx. KRW 3.69T)
- Operating Profit: KRW 1,113,680M (Approx. KRW 1.11T)
- Net Profit: KRW 857,691M (Approx. KRW 857.7B)
- Total Assets: KRW 16,046,197M (Approx. KRW 16.05T)
- Total Liabilities: KRW 6,215,705M (Approx. KRW 6.22T)
- Total Equity: KRW 9,830,492M (Approx. KRW 9.83T)
- External Auditor’s Opinion: Clean/Unmodified (“Appropriate” for both consolidated and separate statements)
- Approved FY2023 Financial Statements (Separate):
- Revenue: KRW 2,938,756M (Approx. KRW 2.94T)
- Operating Profit: KRW 1,204,188M (Approx. KRW 1.20T)
- Net Profit: KRW 945,920M (Approx. KRW 945.9B)
- Dividend Allocation: No cash, property, or stock dividend payouts were declared for this reporting period.
- Board of Directors Appointments:
- New Outside Director & Audit Committee Member: Suh Seoung-hwan (Born June 1956, 3-year term; currently Professor Emeritus at Yonsei University and former Minister of Land, Infrastructure and Transport).
- Board Composition Post-Meeting: Total of 7 directors, including 4 outside directors, maintaining an outside director ratio of 57.14%. The number of outside directors serving on the audit committee is locked at 3.
- Other Approved Agenda: Agenda item regarding the approval of the director compensation limit was passed as originally proposed.
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
- Impact on Fundamental Changes: This disclosure marks the final administrative step validating the audited FY2023 financial statements with an unmodified auditor’s opinion. The official confirmation of the previously reported KRW 3.69 trillion consolidated revenue and KRW 1.11 trillion operating profit solidifies corporate transparency and underpins governance stability, contributing a positive potential impact to the company’s long-term fundamental tracking. Structurally, revenue securely matches ahead of operating profit.
- Risks and Red Flags for Investors: Since all proposed corporate governance agendas successfully passed without any proxy friction or institutional blockages, near-term operational friction remains minimized. However, the absence of any earmarked cash dividend distributions within the final approved text serves as a data point for investors targeting immediate dividend yield metrics. Furthermore, the regulatory filing does not explain any concrete reasons for structural performance trends, meaning market participants should treat this strictly as a confirmation of historical numbers.
📝 Editor’s Comment (by K-STOCK Editor)
The annual ritual of formalizing corporate financials and updating governance frameworks has concluded smoothly with zero proxy friction. With the massive KRW 3.69 trillion revenue performance legally locked in alongside a clean audit stamp, the addition of Professor Suh Seoung-hwan—bringing significant administrative weight from his time as a government minister and university president—broadens the board’s structural oversight capacity. While this type of administrative filing carries no immediate operational triggers to generate sharp price volatility, it provides institutional investors with a clear signal that the corporate governance timeline and regulatory tracking are operating under steady compliance parameters.
📢 Disclaimer and Source Information
Source: This content has been structured and newly written based on official submission data from the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
